Introduction/Background Describe the global survival of ovarian cancer patients treated with HIPEC procedure.

Compare overall survival (OS) and progression-free survival (PFS) among ovarian cancer patients who underwent cytoreduction and HIPEC procedure vs patients treated with systemic chemotherapy.

Methodology Cases: patients treated with cytoreduction and HIPEC (N=46)

Controls: patients treated with systemic chemotherapy (N=92)

Follow-up: 2007–2017

PFS was calculated from the beginning of the treatment to the date when progression, death or the last visit was documented. OS was calculated from the beginning of the treatment to the death or to the last known follow-up.

Demographic, clinical, surgical and outcomes were collected from the clinical records.

Results The estimated median OS in the HIPEC group was 99.1 months vs 38.9 months in the control group (p=0.0002)

PFS was 32.8 months in the HIPEC group and 17.8 months in the control group (p=0.05).

Conclusion Platinum resistance plays an important role in patient survival, with a difference of 40 months between those who are resistant and those who are not at the moment of HIPEC.

This study suggests that CRS and HIPEC in patients with recurrent

Complete cytoreduction (CCR0) was performed in 33 patients (71.7%) and optimal (with residual of less than 0.5 cm) in 13 patients (28.3%).

Severe complications occurred in 11 patients (37.93%).

ovarian cancer may be beneficial compared to conventional secondary debulking or systemic therapy as treatment alone.

The measurement of OS from initial diagnosis is substantially modified to more than 104 months, a figure not seen before in advanced or recurrent disease of this neoplasm

Disclosures The effort of the surgical oncology community to find the ideal patient and the ideal moment for this procedure should be directed not only to treatment, but to a sequence that offers patients a possibility of cure